The durability data significantly strengthens BrainsWay's competitive position in the TMS market, potentially accelerating adoption by providers and supporting reimbursement discussions. Traders should monitor for follow-on publications, payer coverage decisions, and upcoming quarterly results for evidence of commercial impact.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 9 $16.84entry
- T+1 · 5mo ago 0.00%α +1.58% · $16.84
- T+5 · 5mo ago 0.00%α −1.80% · $16.84
- T+20 · 4mo ago 0.00%α −1.39% · $16.84
- T+60 · 3mo ago −10.15%α −14.24% · $15.13
Price Chart
How similar events traded
Executive Summary
BrainsWay presented new 12-month durability data for its SWIFT accelerated Deep TMS protocol at the CTMSS annual meeting, showing over 80% remission rate and a decline in severe functional impairment from 85% to 0% at 12 months. This is the first prospective, randomized controlled trial to demonstrate one-year durability for both accelerated and conventional Deep TMS, building on the FDA clearance received in September 2025. The data strengthens the clinical evidence supporting BrainsWay's platform and could drive adoption among providers and payers.
Key Facts
- Over 80% of SWIFT-treated patients remained in remission at 12 months (clinician-rated).
- Severe functional impairment dropped from 85% at baseline to 0% at 12 months in the SWIFT group.
- Less than 25% of patients required medication change or additional TMS within 12 months.
- Data presented at the 14th Annual Clinical TMS Society Meeting (June 4-6, 2026).
- SWIFT protocol reduces acute-phase clinic visits by 70% vs. standard Deep TMS.
- Study followed 65 patients (73% of the original pivotal trial cohort) over 12 months.
- FDA clearance for SWIFT protocol in MDD was granted in September 2025.
Financial Impact
No financial figures provided; clinical data supports potential market adoption and reimbursement expansion.
Risk Factors
- Data is preliminary and from a conference poster, not yet peer-reviewed.
- Small sample size (65 patients) limits statistical power.
- Competing TMS protocols and alternative depression treatments may erode market share.
- Reimbursement and adoption timelines remain uncertain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-003986 |
| Document: f6k_060826.htm | 0001171843-26-003986 |
| Document: 0001171843-26-003986-index-headers.html | 0001171843-26-003986 |
| Document: 0001171843-26-003986-index.html | 0001171843-26-003986 |
| Document: 0001171843-26-003986.txt | 0001171843-26-003986 |
Track record
5 reports on BRSYF
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +24.28% at T+20 after the Apr 15, 2026 report. 2 of 3 went positive at some point.
Filters
- Jun 9, 202622w ago 6-K Bullish 7/10 Viewing Entry $16.84 to $15.13 Now $10.62 −36.94% ▼ −10.15% −14.24% vs SPY
- May 18, 202626w ago 6-K Neutral 4/10 Entry $16.84 to $15.13 Now $10.62 −36.94% ▼ −10.15% −15.01% vs SPY
- May 13, 202626w ago 6-K Bullish 8/10 Entry $16.84 to $15.13 Now $10.62 −36.94% ▼ −10.15% −14.59% vs SPY
- Apr 20, 202630w ago 20-F Bullish 7/10 Entry $13.55 to $15.13 Now $10.62 −21.62% ▲ +11.66% +4.76% vs SPY
- Apr 15, 202630w ago 6-K Bullish 7/10 Entry $13.55 to $15.13 Now $10.62 −21.62% ▲ +11.66% +3.52% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers